ADCT - ADC Therapeutics to Participate in September Investor Conferences | Benzinga
LAUSANNE, Switzerland, Sept. 05, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE:ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in two investor conferences in September.
Details of the events are as follows:
- Morgan Stanley Global Healthcare Conference - fireside chat on Monday, September 11th from 2:15 p.m. – 2:45 p.m. ET
- Cantor Global Healthcare Conference - fireside chat on Wednesday, September 27th from 4:45 p.m. – 5:15 p.m. ET
Live webcasts of the fireside chats will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website, ir.adctherapeutics.com. A replay of each webcast will be available for approximately 30 days.
About ADC Therapeutics
ADC Therapeutics (NYSE:ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.
ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the ...